Gene therapy study identifies potential new treatment for liver cancer
By Lisa Howard
MicroRNA-22 produced better survival outcomes than current FDA-approved drug in mouse study
(SACRAMENTO)
Gene therapy that induces the body to create microRNA-22 (miR-22), a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma, the most common form of liver cancer.
The miR-22 treatment also reduced liver inflammation and produced better survival outcomes with no observable toxicity compared to the FDA-approved liver cancer treatment lenvatinib.
“This research introduces miR-22 gene therapy as a promising and innovative approach for treating hepatocellular carcinoma,” said Yu-Jui Yvonne Wan, senior author of the study. Wan is a distinguished professor and vice chair for research in the UC Davis Department of Pathology and Laboratory Medicine. “The study's findings suggest that miR-22 therapy could provide better survival outcomes, enhance anti-tumor immunity, improve metabolism and reduce inflammation.”
The University of California filed a patent application for Wan’s discovery of miR-22 for treating hepatic and metabolic diseases. The patent is currently pending.
Left to right, Yu-Jui Yvonne Wan, senior author, and Ying Hu, first author of a new study, looking at the efficacy of microRNA-22 gene therapy for liver cancer.
MicroRNAs’ role in health and disease
MicroRNAs are small molecules that contain ribonucleic acid (RNA), a type of genetic material. MicroRNAs are widely found in plants and animals. They are “non-coding,” meaning they do not make proteins like some other RNA molecules.
In the case of miR-22, it acts like a brake, stopping the production of certain proteins, including cyclin A, protein deacetylases and hypoxia-inducible factor, that can fuel liver cancer growth. A lack of miR-22 is found in hepatocellular carcinoma tumors, and its levels can predict survival time for patients with the disease.
Wan studies the interaction between gut microbes and the liver, what’s known as the gut-liver axis. Her previous research shows that metabolites produced by the gut microbiome help create miR-22 and have anti-cancer benefits. These metabolites include retinoic acid, short-chain fatty acids, bile acids and vitamin D3.
When people have colon or liver cancer, signaling from these metabolites is reduced, which in turn reduces miR-22.
This was a clue for Wan that returning miR-22 to a higher level might act as a treatment for liver cancer. She launched several studies, including one demonstrating miR-22 could suppress liver tumors by targeting both liver and immune cells.
Ying Hu holds a slide with tissue samples. The study examined microRNA-22 gene therapy in mice with a common form of liver cancer.
Gene therapy to test efficacy of miR-22 for liver cancer
For this study, Wan and first author Ying Hu, an assistant professional researcher in Wan’s lab, turned to gene therapy.
Using an inactivated adenovirus, they introduced miR-22 into mice with a single intravenous injection.
The mice treated with the gene therapy were compared with mice treated with the current FDA-approved drug lenvatinib (administered orally once a day), untreated mice and healthy mice.
Both miR-22 and lenvatinib inhibited the progression of the liver cancer compared to untreated mice. However, the miR-22-treated mice had longer survival times without toxicity compared with lenvatinib-treated mice. Some of the study’s key findings:
MiR-22 and lenvatinib reduced serum alanine transaminase (ALT), aspartate aminotransferase (AST), and cholesterol levels, indicating improved liver function.
MiR-22-treated mice showed no blood or organ toxicity.
At five weeks, untreated mice had enlarged livers, making up 33.5% of their body weight. The treated mice had smaller, less diseased livers, with ratios of 10.9% (miR-22) and 12.0% (lenvatinib) of body weight.
The median survival rate was 46 days for the lenvatinib group and 50 days for the miR-22 group.
Two mice treated with miR-22 remained alive for 60 days. In contrast, the survival time for the untreated mice was about 40 days.
MiR-22 treated hepatocellular carcinoma and produced better survival outcomes than lenvatinib.
Liver cancer is a leading cause of death worldwide
Hepatocellular carcinoma is becoming a bigger problem due to rising obesity rates worldwide, including in the U.S.
Drugs to treat hepatocellular carcinoma — sorafenib, lenvatinib, regorafenib, and cabozantinib — are associated with considerable toxicities and poor quality-of-life outcomes. The survival benefit is limited to a few months and the cost is very high.
“The positive findings from this preclinical study give us hope that miR-22 could be a promising alternative to treat hepatocellular carcinoma,” Hu said.
Additional authors include Tahereh Setayesh, Farzam Vaziri, Xuesong Wu and Samuel T. Hwang from UC Davis.
Research for this study was funded by National Institutes of Health grants R01CA222490, R50CA243787 and T32 CA108459-15.
